Programmed cell death (apoptosis) seems to be the principal mechanism whereby anti-oncogenic therapies such as chemotherapy and radiation effect their responses. Resistance to apoptosis, therefore, is probably a principal mechanism whereby tumors are able to overcome these cancer therapies. The transcription factor NF-κB is activated by chemotherapy and by irradiation in some cancer cell lines. Furthermore, inhibition of NF-κB in vitro leads to enhanced apoptosis in response to a variety of different stimuli. We show here that inhibition of NF-κB through the adenoviral delivery of a modified form of IκBα, the inhibitor of NF-κB, sensitizes chemoresistant tumors to the apoptotic potential of TNFα and of the chemotherapeutic compound CPT-11, resulting in tumor regression. These results demonstrate that the activation of NF-κB in response to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and establish the inhibition of NF-κB as a new approach to adjuvant therapy in cancer treatment.
1
. Resistance to chemotherapies may already exist before the initiation of therapy because of overexpression of the multidrug resistance gene product MDR1, which functions to export a variety of chemotherapies from tumor cells 2 . Moreover, chemoresistance (acquired or inducible) may develop in response to chemotherapy by mostly unknown mechanisms. Apoptosis (programmed cell death) seems to be the main mechanism whereby chemotherapy and radiation induce the killing of tumor cells 1, [3] [4] [5] . Apoptosis also serves as a cell-killing mechanism induced by cytokines such as tumor necrosis factor α (TNFα) (ref. 6) . Apoptosis induced by TNFα and by chemotherapy and radiation seem to require, at least partially, the activation of the caspase cascade, leading to proteolytic cleavage of a variety of important proteins and ultimately to cleavage of cellular DNA (refs. 4,6,7) . TNFα, chemotherapy, radiation and other stimuli activate the transcription factor NF-κB, and this response potently suppresses the apoptotic potential of these stimuli in vitro [8] [9] [10] [11] [12] . Here we analyzed the effect of inhibition of NF-κB in parallel with TNFα or chemotherapy treatment on experimental tumors. Our data establish that the inhibition of NF-κB activation in tumors through the adenoviral delivery of a modified form of IκBα, the natural inhibitor of NF-κB (refs. 13,14) , functions to substantially enhance the apoptotic potential of cancer therapies. Thus, NF-κB activation serves as a principal mechanism for inducible resistance to chemotherapy, and inhibition of NF-κB could be a new adjuvant approach for cancer treatment.
TNFα elicits tumor regression after NF-κB inhibition
Although TNFα can elicit apoptosis in some tumor cells in vitro and in some experimental tumor models, limited responses are obtained with systemic delivery of TNFα because of toxicity and resistance of tumor cells to induced cell death 15 . TNFα has shown efficacy in combination with interferon-γ against some sarcomas and melanomas, using limb perfusion approaches 16 . TNFα disrupts tumor vasculature endothelium 17 through reduction of expression of αVβ3 integrin 18 , but does not have a direct killing effect on tumor cells. TNFα can elicit apoptosis in cell culture if NF-κB is inhibited [8] [9] [10] [11] ; thus, we sought to determine if similar results could be attained in tumors in vivo. We generated in nude mice fibrosarcoma tumors derived from HT1080 cells with an empty expression vector (HT1080V) or HT1080 cells expressing a modified form of the NF-κB inhibitor IκBα (HT1080I cells; ref. 8) . The modification of IκBα blocks its ability to be phosphorylated and to be subsequently degraded, thereby preventing NF-κB translocation to the nucleus 19 . HT1080I cells are blocked in their ability to activate NF-κB (ref. 8) . Intratumoral injection of TNFα yields enhanced antitumor effects compared with systemic treatment 15 and systemic delivery of high levels of TNFα is toxic in mice (data not shown). Thus, we assessed the anti-tumor effects after intratumoral administration of TNFα in HT1080V and HT1080I tumors of similar size. HT1080I tumors grow more slowly than HT1080V tumors. The HT1080I tumor mass was eradicated within 7 days, leaving only scar tissue after TNFα treatment (Fig. 1) . Most HT1080I tumors (17 of 20) were eradicated by TNFα, whereas only a few HT1080V tumors (3 of 20) regressed, presumably because of the effect of TNFα on tumor vasculature.
TNFα induces tumor apoptosis when NF-κB is inhibited
TNFα causes 'hemorrhagic necrosis' of tumors through effects on tumor vasculature 17, 18 ; thus, we determined whether the effect of TNFα on HT1080I tumors was through apoptotic or necrotic mechanisms. We collected several HT1080V and HT1080I tumors after 16-24 hours of TNFα treatment and analyzed the samples by TUNEL assay (Fig. 2a-d HT1080I tumors had widespread TUNEL-positive cells, in contrast to the staining of HT1080V tumors (Fig. 2d) , indicating that TNFα elicited tumor cell apoptosis when NF-κB was inhibited. To confirm that TNFα caused tumor regression, we collected the tumor and surrounding soft tissue and examined their histology (Fig 2e-h ). The HT1080I tumor treated with TNF regressed and was replaced by scar tissue consisting mainly of fibroblasts ( Fig. 2h ). There was some regression of the HT1080V tumor in response to TNF (Fig. 2g ). Although the central portion of the tumor mass was destroyed, a peripheral rim of apparently viable tumor tissue was spared (data not shown).
Although we have no direct data on this, our result is consistent with reports showing that TNFα disrupts tumor microvasculature, leading to tumor necrosis 17, 18 .
Potentiation of chemotherapy-induced cell death in vitro
To explore gene therapy approaches relevant to the inhibition of NF-κB, we used cDNA encoding the 'super-repressor' form of IκBα (ref. 19 ) cloned into an adenovirus 5 vector to produce replication-defective Ad.CMV.IκBα (ref. 20) . To determine if the virus was effective in inhibiting NF-κB, we infected HT1080 cells with the control adenovirus Ad.CMV3 or with Ad.CMV.IκBα and treated these cells with TNFα. Ad.CMV.IκBα, but not the control virus, blocked NF-κB induction and led to considerable cell death in the TNFα-treated cells (data not shown). Next, we determined whether the IκBα-encoding virus would enhance apoptosis in HT1080 tumors in response to TNFα. Systemic delivery of TNFα in combination with the intratumoral injection of either control Ad.CMV3 or Ad.CMV.IκBα produced lethal toxicity in the mice (data not shown). We therefore focused on enhancing chemotherapeutic responses in tumors. The chemotherapeutic compound camptothecin (CPT), a topoisomerase I inhibitor, is effective against a variety of tumors 21 . Consistent with reports on topoisomerase inhibitors and other chemotherapies 8, [22] [23] [24] , we found that camptothecin potently activated NF-κB in the HT1080 fibrosarcoma cells (Fig. 3a) . NF-κB activation reached a maximum after 2 hours and was sustained in the nucleus after 7 hours. CPT-11, an analog of camptothecin, has broad anti-tumor function, and is one of the most promising anticancer drugs now in clinical trials 25 . The active metabolite of CPT-11, SN38, is responsible for anti-tumor activity in vivo 26 . Therefore, we determined whether SN38 activated NF-κB. SN38 induced nuclear translocation of NF-κB in a dosedependent manner and at a concentration as low as 0.1 µM (Fig.  3b) . The induced NF-κB was a classical heterodimer with a 50-kDa subunit and a 65-kDa subunit, as confirmed by antibody 'supershift' analysis with p50 and p65 antibodies (Fig. 3c) . Our p50 antibody is ineffective in 'supershifting' a p50-p65 heterodimer. To determine whether the activation of NF-κB had an effect on CPT-and SN38-induced cytotoxicity, we treated HT1080V or HT1080I cells with CPT or SN38 for 24 hours. The cytotoxicity generated by CPT or SN38 was enhanced considerably by inactivation of NF-κB, although less so at the lower concentrations of drug (Fig. 3d) .
Enhanced CPT-11-mediated apoptosis and tumor regression
To determine if the inhibition of NF-κB would enhance antitumor responses of CPT-11, we established HT1080 tumors by subcutaneous injection of cells in nude mice. We injected tumors with either control virus (Ad.CMV3), the adenovirus encoding the 'super-repressor' form of IκBα (Ad.CMV.IκBα) or vehicle alone. We then treated mice systemically with either CPT-11 or with PBS and measured tumor volume for 20 days. Neither CPT-11 alone nor Ad.CMV.IκBα alone resulted in inhibition of tumor growth (Fig. 4) . There was enhanced fibrosarcoma growth in the presence of chemotherapy alone. However, combined systemic CPT-11 treatment and tumor injection with Ad.CMV.IκBα (but not Ad.CMV3) elicited significant inhibition of tumor growth (Fig. 4) . Furthermore, inhibition of tumor cell growth in vitro with combined chemotherapy and inhibition of NF-κB was attained with tumor cell lines expressing either wildtype or mutant p53, although the presence of wild-type p53 seemed to enhance the cell death response (J.C.C., R.L. and A.S.B., unpublished data).
To determine if the anti-tumor effect was elicited by apoptosis, we isolated tumors 48 hours after the initial viral treatment and 24 hours after the initial CPT-11 treatment and sectioned them for histology and TUNEL assays. CPT-11 treatment plus inhibition of NF-κB led to tumors with mostly apoptotic cells (Fig. 5) . Treatment with CPT-11 alone or with Ad.CMV.IκBα alone yielded almost no apoptotic responses in the tumors. Moreover, NF-κB was activated in the tumors treated with CPT-11 and this activation was suppressed by expression of IκBα (J.C.C, R.L. and A.S.B., unpublished data).
To determine if this enhanced anti-tumor response could be attained in other tumor models, we explored the use of Ad.CMV.IκBα in combination with CPT-11 in the Lovo colorectal tumor model. CPT-11 and Ad.CMV.IκBα in combination led to considerable suppression of tumor growth associated with a substantially enhanced apoptotic response, whereas CPT-11 or Ad.CMV.IκBα alone were ineffective at inducing these responses (Table) . These results show that CPT-11 was unable to elicit an apoptotic response in fibrosarcoma or colorectal tumors unless NF-κB was inhibited, establishing NF-κB as a principal mediator of inducible chemoresistance.
Discussion
Many cancer cells either show chemo-or radioresistance or acquire resistance after therapy 27, 28 . Increased concentrations of cytotoxic drugs and higher dosages of irradiation fail to improve the pharmacotherapeutic response in resistant cancer cells. Thus, research efforts are aimed at determining the regulatory events involved in chemo-and radioresistance. Resistance to apoptosis controls the ability of tumors to withstand high levels of chemotherapy and radiation 1 . Moreover, cells that are resistant to apoptosis seem to have a growth advantage in tumors 29, 30 . Therefore, the development of approaches to lower the apoptotic threshold within tumor cells is likely to prove useful both as a direct cancer treatment and in combination with radiation and chemotherapy.
Resistance to cancer chemotherapy can be caused in many ways. One mechanism of chemoresistance is caused by overexpression of MDR1, a transmembrane protein that functions to export chemotherapeutic compounds from cells 2 . Another mechanism seems to be inducible or acquired resistance of the tumor to apoptosis, which blocks the ability of chemotherapies and radiation to induce tumor cell death 2 . Acquired resistance 
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may result from mutations in p53 or overexpression of antiapoptotic proteins such as Bcl-2. Although there may be many mechanisms by which resistance to apoptosis is achieved in tumors, our data indicate that a main pathway involved in inducible resistance is the activation of the transcription factor NF-κB within tumor cells in response to chemotherapy or TNFα. In either case, inhibition of cancer therapy-induced NF-κB activation strongly enhances the apoptotic potential of these stimuli. Our findings probably explain the lack of efficacy of TNFα in cancer trials 15, 16 and the reduced efficacy of chemotherapies in general 1 and identify an important mechanism whereby tumors are induced to become resistant to cancer therapy. Consistent with our results, the use of combined approaches in cancer therapies has been described [31] [32] [33] , and it is much more efficacious than a single type of treatment.
How does NF-κB activation suppress apoptosis in tumor cells in response to TNFα or chemotherapy? Because the ability of TNFα to elicit an apoptotic response typically requires the inhibition of protein synthesis 34 , activation of NF-κB was assumed to induce transcription of genes that encode gene products that function to feedback and block apoptosis. Consistent with this, four gene products (TRAF1 and 2 and c-IAP1 and 2) are upregulated by NF-κB at the mRNA level that block the ability of TNFα to activate the apical caspase, caspase-8 (ref. 35) . Like TNFα, chemotherapy induces apoptosis through induction of the caspase cascade. c-IAP1 and 2 expression alone can suppress etoposide-induced apoptosis 35 , consistent with the ability of these proteins to block activation of the downstream caspases, caspase-3 and -7 (ref. 36) . Apoptosis induced by chemotherapy seems to involve the upregulation of Fas ligand and induced cell killing controlled by Fas, at least in some cell types 3 . At present, it is not known whether the activation of NF-κB suppresses Fas-mediated cell killing and, if so, whether the same NF-κB-regulated gene products that suppress TNFα-induced apoptosis can suppress Fas-induced apoptosis. Although p53 is involved in apoptosis induced by chemotherapy and radiation 5 , our preliminary data (unpublished) indicate that the enhanced apoptosis resulting from the combination of NF-κB inhibition and chemotherapy treatment is at least partially p53-independent. This is consistent with observations that oncogenic Ras induces apoptosis in a p53-independent manner when NF-κB is inhibited 37 . Our results with TNFα and camptothecins provide a conceptual basis for improving the efficacy of chemotherapy and biologic-based anti-cancer therapy. The main target for TNFα in clinical cancer trials is the tumor microvasculature 17, 18 . Our studies indicate that TNFα in parallel with NF-κB inhibition leads to direct tumor cell killing. At present, it is unclear whether this combined approach would augment or suppress the TNFα effect on disruption of microvasculature. Combined cancer treatment strategies that use inhibition of NF-κB may substantially augment the sensitivity of chemoresistant tumors and improve the clinical response rates in these tumors. For neoplasms that show chemosensitivity, the combined strategy may lower the level of chemotherapy needed to effectively elicit an anti-cancer response. Given the results of studies with two tumor model systems and with a variety of tumor cell lines and chemotherapies, our results may be applicable to diverse tumors. However, we cannot rule out the possibility that certain tumors or certain chemotherapies may require NF-κB for inducing cell death.
The apoptotic response elicited in the tumors by CPT-11 and Ad.CMV.IκBα injection is widespread. In fact, experimental conditions can be modified so that near-complete tumor regression is obtained by this approach (J.C.C, R.L. and A.S.B., unpublished data). LacZ staining after injection of HT1080 tumors with Ad.LacZ indicates that approximately 50% of tumor cells express Tumors were injected with virus or PBS, then mice were injected with CPT-11 or PBS 24 h later. +, 0-25% positive; ++, 26-50% positive; +++, 51-75% positive; and ++++, 76-100% positive. a The growth response ratio was calculated as the mean tumor volume on day 8 after treatment with CPT-11 or PBS (control).
b Super-repressor-IκBα transgene expression measured as the percentage of cells stained positive for the hemagluttinin-tagged epitope on the supre-repressor IκBα protein.
c Apoptotic score measured as the percentage of cells stained TUNEL-positive 24h after treatment.
